An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma

Gene Expression Levels as Predictive Markers of Outcome in Pancreatic Cancer after Gemcitabine-Based Adjuvant Chemotherapy

(2015) Hayato Fujita et al.   NEOPLASIA

Differential Expression of ERCC1 in Pancreas Adenocarcinoma: High Tumor Expression is Associated with Earlier Recurrence and Shortened Survival after Resection

(2011) Shishir K. Maithel et al.   ANNALS OF SURGICAL ONCOLOGY

HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma

(2011) R. J. Jones et al.   BLOOD

Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer

(2011) D. Ansari et al.   BRITISH JOURNAL OF SURGERY

Molecular Predictors of Response to Chemotherapy in Non-Small Cell Lung Cancer

(2011) Jenny Andrews et al.   CANCER JOURNAL

Ribonucleotide Reductase Small Subunit M2B Prognoses Better Survival in Colorectal Cancer

(2011) X. Liu et al.   CANCER RESEARCH

Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines

(2011) Giuseppe Pasqualetti et al.   LUNG CANCER

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adjuvant therapy of pancreatic cancer

(2010) Andreas Hilbig et al.   Expert Review of Anticancer Therapy

ERCC1: impact in multimodality treatment of upper gastrointestinal cancer

(2010) Ralf Metzger et al.   Future Oncology

The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer

(2010) Lars Petter Jordheim et al.   LANCET ONCOLOGY

Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer

(2009) Gabriella Ferrandina et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma

(2009) H Akita et al.   ONCOGENE

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

(2008) Volker Heinemann et al.   BMC CANCER

Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer

(2008) James J. Farrell et al.   GASTROENTEROLOGY

A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas

(2008) Steven Attia et al.   INVESTIGATIONAL NEW DRUGS